Can RNAi-mediated hsp90α knockdown in combination with 17-AAG be a therapy for glioma?

Adi Mehta; Amal Shervington; John Howl; Sarah Jones; Leroy Shervington

doi:10.1016/j.fob.2013.06.002

Can RNAi-mediated hsp90α knockdown in combination with 17-AAG be a therapy for glioma?

Adi Mehta, Amal Shervington^*, John Howl, Sarah Jones, Leroy Shervington

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

6 Citations (SciVal)

Original language	English
Pages (from-to)	271-278
Number of pages	8
Journal	FEBS Open Bio
Volume	3
DOIs	https://doi.org/10.1016/j.fob.2013.06.002
Publication status	Published (VoR) - 2013

Funding

This study was supported by a Grant from the Sydney Driscoll Neuroscience Foundation (SDNF) and the School of Pharmacy and Biomedical Sciences (UCLan). The work was also supported by the Estonian Government through the targeted financing SF0180027s08 and the European Regional Development Fund [project Tumor-Tech (3.2.1001.11–0008) ].

Funders	Funder number
Estonian Government	SF0180027s08
Sydney Driscoll Neuroscience Foundation
University of Central Lancashire
European Regional Development Fund	3.2.1001.11–0008

Keywords

Akt
Cell penetrating peptides
Cell-cycle arrest
GBM
Glioblastoma
Hsp90 inhibitor
Hsp90α
Sihsp90α/CPP complex
Tat

Access to Document

10.1016/j.fob.2013.06.002

Cite this

@article{996b2e6219ac4e10b3a04282107653e3,

title = "Can RNAi-mediated hsp90α knockdown in combination with 17-AAG be a therapy for glioma?",

keywords = "Akt, Cell penetrating peptides, Cell-cycle arrest, GBM, Glioblastoma, Hsp90 inhibitor, Hsp90α, Sihsp90α/CPP complex, Tat",

author = "Adi Mehta and Amal Shervington and John Howl and Sarah Jones and Leroy Shervington",

year = "2013",

doi = "10.1016/j.fob.2013.06.002",

language = "English",

volume = "3",

pages = "271--278",

journal = "FEBS Open Bio",